Key Points
-
The study of IL-1β and IL-1 receptor antagonist in monogenic autoinflammatory diseases, and of IL-6 in systemic-onset juvenile idiopathic arthritis (sJIA), led to new treatment options by forward translation
-
The inefficiency of anti-TNF therapy in TNF receptor-associated periodic syndrome and the beneficial response to IL-1β blockade in sJIA stimulated reverse translational studies of the pathophysiological role of these cytokines
-
Biomarkers such as S100 proteins, IL-18 or serum amyloid A aid differential diagnosis and enable monitoring of disease activity and prediction of disease outcome
-
Autoinflammatory components define heterogeneous patient subgroups, which can be further classified by use of functional in vitro assays to identify cellular dysfunction and contribute to the understanding of disease pathophysiology
-
The integration of molecular diagnostics and in vitro analysis of dysfunctional pathways to characterize disease subgroups enable tailoring of treatment regimens and the identification of new therapeutic targets
Abstract
Translational research approaches brought major changes to the understanding and treatment options of autoinflammatory diseases. Patients with common complex multifactorial diseases such as systemic-onset juvenile idiopathic arthritis (sJIA), and particularly those with rare monogenic autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) or TNF receptor-associated periodic syndrome (TRAPS), benefited from a deeper understanding of the pathophysiological mechanisms and new treatment options emerging from preclinical studies. The study of IL-1 and IL-6 in this context led to novel therapies by forward translation. Conversely, effective treatment of sJIA and TRAPS with IL-1 blockade stimulated reverse translational efforts to study the pathophysiology of these cytokines in autoinflammatory diseases. These translational efforts led to the discovery of biomarkers such as S100 proteins, IL-18 or serum amyloid A, which are components of the inflammatory process, support diagnosis and allow for monitoring of disease activity, helping to predict patient outcomes. The ongoing characterization of autoinflammatory diseases in individual patients has led to classification into heterogeneous subgroups. Further characterization of relevant subgroups and the design of tailored treatment regimens, as well as the identification of new therapeutic targets and treatment options, are the major future challenges in the field of autoinflammatory diseases, particularly for paediatric rheumatologists.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agostini, L. et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319–325 (2004).
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A. & Kolodner, R. D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29, 301–305 (2001).
Goldbach-Mansky, R. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 355, 581–592 (2006).
Hawkins, P. N., Lachmann, H. J. & McDermott, M. F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583–2584 (2003).
Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479–1486 (2005).
Kessel, C., Holzinger, D. & Foell, D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin. Immunol. 147, 229–241 (2013).
Maeno, N. et al. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum. 46, 2539–2541 (2002).
Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361–2371 (2007).
Sha, W. et al. Human NLRP3 inflammasome senses multiple types of bacterial RNAs. Proc. Natl Acad. Sci. USA 111, 16059–16064 (2014).
Zhong, Y., Kinio, A. & Saleh, M. Functions of NOD-like receptors in human diseases. Front. Immunol. 4, 333 (2013).
Gattorno, M. et al. Distinct expression pattern of IFN-α and TNF-α in juvenile idiopathic arthritis synovial tissue. Rheumatology (Oxford) 46, 657–665 (2007).
Tassi, S. et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretion. Proc. Natl Acad. Sci. USA 107, 9789–9794 (2010).
Carta, S. et al. Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes. Ann. Rheum. Dis. 71, 1577–1581 (2012).
Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426–2437 (2009).
Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620–628 (2011).
Rossi-Semerano, L. et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 132, e1043–e1047 (2013).
Caorsi, R. et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res. Ther. 15, R33 (2013).
Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779–1785 (2004).
Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443–2452 (2008).
Kuemmerle-Deschner, J. B. et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70, 2095–2102 (2011).
Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009).
Lovell, D. J., Bowyer, S. L. & Solinger, A. M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283–1286 (2005).
Kolly, L. et al. Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1β production. J. Allergy Clin. Immunol. 131, 1635–1643 (2013).
Stojanov, S. et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and TH1 activation responsive to IL-1 blockade. Proc. Natl Acad. Sci. USA 108, 7148–7153 (2011).
Crow, Y. J. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr. Opin. Immunol. 32, 7–12 (2015).
Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371, 507–518 (2014).
Horneff, G. et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63, 1638–1644 (2004).
Quartier, P. et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48, 1093–1101 (2003).
Allantaz, F. et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204, 2131–2144 (2007).
Barnes, M. G. et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2102–2112 (2009).
Foell, D. et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 50, 1286–1295 (2004).
Wittkowski, H. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58, 3924–3931 (2008).
de Benedetti, F. & Martini, A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 52, 687–693 (2005).
de Benedetti, F. et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99, 643–650 (1997).
Martini, A. et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 344, 1052–1054 (1994).
Cangemi, G. et al. Diagnostic potential of hepcidin testing in pediatrics. Eur. J. Haematol. 90, 323–330 (2013).
Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271–1276 (2004).
Yokota, S. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818–825 (2005).
de Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385–2395 (2012).
Gattorno, M. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 1516–1520 (2008).
Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505–1515 (2008).
Lequerre, T. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302–308 (2008).
Nigrovic, P. A. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63, 545–555 (2011).
Quartier, P. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70, 747–754 (2011).
Vastert, S. J. et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66, 1034–1043 (2014).
Ruperto, N. et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 64, 557–567 (2012).
Ruperto, N. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2396–2406 (2012).
McDermott, M. F. et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97, 133–144 (1999).
Bulua, A. C. et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 64, 908–913 (2012).
Simon, A. et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am. J. Med. 117, 208–210 (2004).
Ter Haar, N. et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann. Rheum. Dis. 72, 678–685 (2013).
Brizi, M. G., Galeazzi, M., Lucherini, O. M., Cantarini, L. & Cimaz, R. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann. Intern. Med. 156, 907–908 (2012).
Bulua, A. C. et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 208, 519–533 (2011).
Simon, A. et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc. Natl Acad. Sci. USA 107, 9801–9806 (2010).
Dickie, L. J. et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann. Rheum. Dis. 71, 2035–2043 (2012).
Rubartelli, A., Gattorno, M., Netea, M. G. & Dinarello, C. A. Interplay between redox status and inflammasome activation. Trends Immunol. 32, 559–566 (2011).
Bachetti, T. et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann. Rheum. Dis. 72, 1044–1052 (2013).
Frenkel, J. et al. Lack of isoprenoid products raises ex vivo interleukin-1β secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 46, 2794–2803 (2002).
Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222–230 (2011).
Knowlton, N. et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum. 60, 892–900 (2009).
Foell, D. et al. Proinflammatory S100A12 can activate human monocytes via Toll-like receptor 4. Am. J. Respir. Crit. Care Med. 187, 1324–1334 (2013).
Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042–1049 (2007).
Frosch, M. et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of Toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 883–891 (2009).
Kallinich, T., Wittkowski, H., Keitzer, R., Roth, J. & Foell, D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann. Rheum. Dis. 69, 677–682 (2010).
Ling, X. B. et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics 10, 4415–4430 (2010).
Wittkowski, H. et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum. 56, 4174–4181 (2007).
Wittkowski, H. et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann. Rheum. Dis. 70, 2075–2081 (2011).
Holzinger, D. et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 71, 974–980 (2012).
Moncrieffe, H. et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford) 52, 1467–1476 (2013).
Foell, D. et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266–1273 (2010).
Gerss, J. et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann. Rheum. Dis. 71, 1991–1997 (2012).
Rothmund, F. et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) 66, 949–955 (2014).
Dinarello, C. A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 27, 98–114 (2007).
Dinarello, C. A. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. 11, 483–486 (2000).
Dinarello, C. A. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J. Allergy Clin. Immunol. 103, 11–24 (1999).
Leung, B. P. et al. A role for IL-18 in neutrophil activation. J. Immunol. 167, 2879–2886 (2001).
Dinarello, C. A. et al. Overview of interleukin-18: more than an interferon-γ inducing factor. J. Leukoc. Biol. 63, 658–664 (1998).
Jelusic, M. et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin. Rheumatol. 26, 1332–1334 (2007).
Lotito, A. P., Campa, A., Silva, C. A., Kiss, M. H. & Mello, S. B. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J. Rheumatol. 34, 823–830 (2007).
Shimizu, M., Nakagishi, Y. & Yachie, A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61, 345–348 (2013).
Mazodier, K. et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106, 3483–3489 (2005).
Shimizu, M. et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 49, 1645–1653 (2010).
Laiho, K., Tiitinen, S., Kaarela, K., Helin, H. & Isomaki, H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin. Rheumatol. 18, 122–123 (1999).
Singh, G., Kumari, N., Aggarwal, A., Krishnani, N. & Misra, R. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J. Rheumatol. 34, 371–373 (2007).
Parmelee, D. C. et al. Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human high-density lipoprotein. Biochemistry 21, 3298–3303 (1982).
Urieli-Shoval, S., Linke, R. P. & Matzner, Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 7, 64–69 (2000).
Merlini, G. & Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583–596 (2003).
Pepys, M. B. Amyloidosis. Annu. Rev. Med. 57, 223–241 (2006).
Lane, T. et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65, 1116–21 (2013).
van den Broek, T. et al. Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis. Ann. Rheum. Dis. 74, 470–472 (2015).
Balow, J. E. Jr et al. Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts. Ann. Rheum. Dis. 72, 1064–1070 (2013).
Negm, O. H. et al. A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS). Eur. J. Immunol. 44, 2096–2110 (2014).
Banchereau, R., Cepika, A. M. & Pascual, V. Systems approaches to human autoimmune diseases. Curr. Opin. Immunol. 25, 598–605 (2013).
Canna, S. W. et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140–1146 (2014).
de Jager, W. et al. Defective phosphorylation of interleukin-18 receptor β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2782–2793 (2009).
Villanueva, J. et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res. Ther. 7, R30–R37 (2005).
Grom, A. A. et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142, 292–296 (2003).
Kaufman, K. M. et al. Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 66, 3486–3495 (2014).
Rieber, N. et al. A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. Clin. Immunol. 157, 56–64 (2015).
Haverkamp, M. H., van de Vosse, E., Goldbach-Mansky, R. & Holland, S. M. Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS). Clin. Exp. Immunol. 177, 720–731 (2014).
Omenetti, A. et al. Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann. Rheum. Dis. 73, 462–469 (2014).
Rubartelli, A. Redox control of NLRP3 inflammasome activation in health and disease. J. Leukoc. Biol. 92, 951–958 (2012).
Kitamura, A., Sasaki, Y., Abe, T., Kano, H. & Yasutomo, K. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J. Exp. Med. 211, 2385–2396 (2014).
Avau, A. et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-gamma. Arthritis Rheumatol. 66, 1340–1351 (2014).
Behrens, E. M. et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J. Clin. Invest. 121, 2264–2277 (2011).
Qiao, Y. et al. Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and Toll-like receptor signaling. Immunity 39, 454–469 (2013).
Yoshitaka, T. et al. Enhanced TLR–MYD88 signaling stimulates autoinflammation in SH3BP2 cherubism mice and defines the etiology of cherubism. Cell Rep. 8, 1752–1766 (2014).
Venereau, E. et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519–1528 (2012).
Liu, Y. et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 64, 895–907 (2012).
Zielinski, C. E. et al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 484, 514–518 (2012).
Record, J. L., Beukelman, T. & Cron, R. Q. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J. Rheumatol. 38, 180–181 (2011).
Nigrovic, P. A. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 66, 1405–1413 (2014).
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
So, A. et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62, 3064–3076 (2010).
Lee, G. S. et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492, 123–127 (2012).
Papin, S. et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1β processing. Cell Death. Differ. 14, 1457–1466 (2007).
Chae, J. J. et al. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34, 755–768 (2011).
Chae, J. J. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc. Natl Acad. Sci. USA 103, 9982–9987 (2006).
Shoham, N. G. et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl Acad. Sci. USA 100, 13501–13506 (2003).
Cortesio, C. L., Wernimont, S. A., Kastner, D. L., Cooper, K. M. & Huttenlocher, A. Impaired podosome formation and invasive migration of macrophages from patients with a PSTPIP1 mutation and PAPA syndrome. Arthritis Rheum. 62, 2556–2558 (2010).
Jeru, I. et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc. Natl Acad. Sci. USA 105, 1614–1619 (2008).
Borghini, S. et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum. 63, 830–839 (2011).
D'Osualdo, A. et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 54, 998–1008 (2006).
Nedjai, B. et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 273–283 (2008).
van der Burgh, R. et al. Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. J. Biol. Chem. 289, 27757–27765 (2014).
van der Burgh, R. et al. Defects in mitochondrial clearance predispose human monocytes to interleukin-1beta hypersecretion. J. Biol. Chem. 289, 5000–5012 (2014).
Valdearcos, M. et al. Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. J. Biol. Chem. 287, 10894–10904 (2012).
Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033–2045 (2009).
Kanazawa, N. et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-κB activation: common genetic etiology with Blau syndrome. Blood 105, 1195–1197 (2005).
Jordan, C. T. et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 90, 784–795 (2012).
Zhou, Q. et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N. Engl. J. Med. 370, 911–920 (2014).
Acknowledgements
D.H. acknowledges support from the Interdisciplinary Centre of Clinical Research (IZKF), Münster, Germany (Clinical Research Award CRA04). D.H. and C.K. acknowledge support from the German Ministry for Education and Science (BMBF 01GM08100, AID-Net). C.K. acknowledges support from the Innovative Medical Research (IMF) program, Münster, Germany (Research Grant KE121201).
Author information
Authors and Affiliations
Contributions
All authors researched the data for the article, provided substantial contributions to discussion of its content, wrote the article and undertook review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
D.H. declares that he has received speaker's fees from Novartis. M.G. declares that he has received speaker's and consultancy fees from Novartis and SOBI. C.K. and A.O. declare no competing interests.
Rights and permissions
About this article
Cite this article
Holzinger, D., Kessel, C., Omenetti, A. et al. From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol 11, 573–585 (2015). https://doi.org/10.1038/nrrheum.2015.79
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.79
This article is cited by
-
Establishment and analysis of a novel diagnostic model for systemic juvenile idiopathic arthritis based on machine learning
Pediatric Rheumatology (2024)
-
The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever
Rheumatology International (2023)
-
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting
Nature Reviews Rheumatology (2022)
-
LPS and oxLDL-induced S100A12 and RAGE expression in carotid arteries of atherosclerotic Yucatan microswine
Molecular Biology Reports (2022)
-
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases
Nature Reviews Rheumatology (2021)